Wells Fargo & Company Lowers Clorox (NYSE:CLX) Price Target to $135.00

Clorox (NYSE:CLX) had its price target dropped by equities researchers at Wells Fargo & Company from $140.00 to $135.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “underweight” rating on the stock. Wells Fargo & Company‘s price target suggests a potential downside of 2.34% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. Jefferies Financial Group raised shares of Clorox from an “underperform” rating to a “hold” rating and set a $145.00 target price for the company in a research note on Tuesday, March 26th. Barclays decreased their target price on shares of Clorox from $136.00 to $132.00 and set an “underweight” rating for the company in a research note on Thursday. Citigroup decreased their target price on shares of Clorox from $155.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday. Evercore ISI decreased their target price on shares of Clorox from $145.00 to $142.00 and set an “underperform” rating for the company in a research note on Wednesday. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $160.00 target price on shares of Clorox in a research note on Tuesday, March 26th. Four investment analysts have rated the stock with a sell rating and thirteen have issued a hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $146.43.

Clorox Price Performance

CLX stock opened at $138.23 on Thursday. Clorox has a 1 year low of $114.68 and a 1 year high of $176.24. The company has a market cap of $17.17 billion, a P/E ratio of 71.62, a PEG ratio of 2.08 and a beta of 0.44. The firm has a 50-day moving average of $148.74 and a 200 day moving average of $143.08. The company has a debt-to-equity ratio of 9.73, a current ratio of 0.90 and a quick ratio of 0.57.

Clorox (NYSE:CLX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.38. Clorox had a net margin of 3.33% and a return on equity of 302.49%. The company had revenue of $1.81 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the prior year, the firm earned $1.51 earnings per share. Clorox’s revenue was down 5.3% on a year-over-year basis. On average, sell-side analysts forecast that Clorox will post 5.85 EPS for the current year.

Institutional Investors Weigh In On Clorox

Large investors have recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC grew its position in Clorox by 308.5% in the 1st quarter. Venturi Wealth Management LLC now owns 192 shares of the company’s stock worth $29,000 after purchasing an additional 145 shares during the period. Northwest Financial Advisors bought a new stake in Clorox in the 4th quarter worth approximately $29,000. GoalVest Advisory LLC bought a new stake in Clorox in the 1st quarter worth approximately $31,000. Core Wealth Advisors Inc. bought a new stake in Clorox in the 4th quarter worth approximately $29,000. Finally, Fortitude Family Office LLC bought a new stake in Clorox in the 4th quarter worth approximately $29,000. Institutional investors own 78.53% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.